Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Anaptysbio Inc.
Headquarters: San Diego, CA, United States of America
Website: https://www.anaptysbio.com/
Year Founded: 2005
Status: Public
Industry Sector: HealthTechnology
CEO: Daniel R. Faga, MBA
Number Of Employees: 136
Enterprise Value: $359,867,680
PE Ratio: -3.59
Exchange/Ticker 1: NASDAQ:ANAB
Exchange/Ticker 2: N/A
Latest Market Cap: $571,935,808
BioCentury | Feb 20, 2025
Product Development
Solid produces best-in-class biomarker data among DMD gene therapies
BioCentury’s latest Clinical Report highlights a pair of value-driving readouts
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: Bispecifics poised to enter new era
Decade after first approval, bispecifics on the precipice of going mainstream
BioCentury | Dec 12, 2024
Data Byte
Candel leads biotech gainers amid wave of data readouts
Prostate cancer data lead to a nearly 70% stock bump; dermatitis data sink Q32 shares
BioCentury | Nov 5, 2024
Product Development
Are PD-1 agonists finally on the verge of impacting inflammation?
Eli Lilly is out of the race, but other companies believe they have differentiated products
BioCentury | Aug 16, 2024
Finance
Public Equity Report: AnaptysBio, Avidity draw nine-digit offerings
Plus: MeiraGTx, scPharmaceuticals each raise $50M
BioCentury | Jun 13, 2024
Emerging Company Profile
Santa Ana: Leveraging human multi-omic data for precision immunology
Versant-founded immunology play launches with $168M to create biologics targeted to specific cell types
BioCentury | Oct 9, 2023
Regulation
Oct. 9 Quick Takes: Setback for Alnylam’s amyloidosis program
Plus: Pfizer’s Bourla posts message of support for Israel, and updates from AnaptysBio, AstronauTx, LimmaTech, GSK, Zhifei and Pixelgen
BioCentury | Sep 20, 2023
Management Tracks
Orwin succeeds Topper as AnaptysBio’s chair
Plus: CDMOs Catalent and Rentschler announce executive changes, and updates from Parexel, Santander, CorriXR and more
BioCentury | Dec 22, 2022
Regulation
Dec. 21 Quick Takes: Cash for NASH as Madrigal and Terns raise funds
Plus: FDA, EMA reviewing Pfizer’s etrasimod for ulcerative colitis and updates from ADC, AZ, CytoDyn, NGM-Merck and more
BioCentury | Sep 2, 2022
Politics, Policy & Law
Sept. 1 Quick Takes: setback for FTC over Illumina’s Grail acquisition
Plus CDC recommends BA.4/BA.5 updated boosters, and updates from CHMP, Y-mAbs and more
Items per page:
1 - 10 of 118